Video content above is prompted by the following: 4. How do the treatment options evolve as a child ages? a. FDA labeling (dupilumab ≥ 6 months, lebrikizumab ≥ 12 years, tralokinumab ≥ 12 years, ...
Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease. Both rare pediatric disease and orphan drug designations from ...
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit.
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) ...
Tina Tan, MD, comments on a severe respiratory season, stresses timely vaccination ...
In this discussion, leading experts weigh in on the importance of scientific integrity, proactive advocacy, and the crucial role of vaccinations in pediatric health. As the landscape of pediatric ...
"Less pain and no need for sedation are major benefits," said Jon Matthew Farber, MD, in this edition of Journal Club. A case report describes how physicians in the emergency department of a Korean ...
LIB Therapeutics has announced that the FDA has accepted its biologics license application (BLA) for lerodalcibep, a treatment designed to lower low-density lipoprotein cholesterol (LDL-C) in patients ...
Colleen Sloan, PA-C, RDN, discussed how the 5 senses can affect a child's appetite, as well as how to use food play to get children to try new foods. Imagine biting into a crisp apple, only to find it ...
His mother reported that the nail had developed a green discoloration and had begun to detach approximately 1 week prior to the visit. An 8-year-old boy presented to the pediatrician’s office for ...
Most children with MIS-C recover within 6 months, with heart function and overall health improving significantly, according to a new study. A new study on multisystem inflammatory syndrome in children ...
Venous thromboembolism (VTE) is a rare but life-threatening condition in pediatrics, posing unique challenges in treatment and prevention within this age group. VTE incidence in pediatric patients has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results